Debevoise & Plimpton LLP is advising Clayton, Dubilier & Rice (“CD&R”) in the financing aspects of its exclusive negotiations for the potential purchase of a 50% controlling stake in Opella, the French-headquartered consumer healthcare company.

The acquisition would place an enterprise value on Opella of c.€16 billion. Opella is the third-largest business worldwide in the over-the-counter and vitamins, minerals & supplements market, serving more than half a billion consumers.

As part of the transaction, Sanofi would remain a significant shareholder in Opella.

For full details, see the official release here.

The Debevoise team advising CD&R on the financing aspects of the deal is being led by partner Alan Davies, and includes partners E. Raman Bet-Mansour, Cécile Beurrier, Pierre Maugüé, Brett Novick, Nicholas Pellicani and Matthew Saronson, international counsel Christopher Dortschy, Philippe Tengelmann and Gregg Young, and associates Patrick Dixon, Tiffany Chow, Lina Hamidou, Carly Hill, Rosanne Lariven, Evgenii Lebedev, Weichi Liu, Lukas Ott, John Satira, Alfred Scott, Timothy Shin, Brad Taylor, and Henry Treble.